A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Public ClinicalTrials.gov record NCT07667803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
Study identification
- NCT ID
- NCT07667803
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 4,500 participants
Conditions and interventions
Conditions
Interventions
- Elecoglipron Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2026
- Primary completion
- Jul 30, 2028
- Completion
- Jul 29, 2029
- Last update posted
- Jun 24, 2026
2026 – 2029
United States locations
- U.S. sites
- 26
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35205 | — |
| Research Site | Chandler | Arizona | 85225 | — |
| Research Site | Lincoln | California | 95648 | — |
| Research Site | Clearwater | Florida | 33765 | — |
| Research Site | Woodstock | Georgia | 30189 | — |
| Research Site | Indianapolis | Indiana | 46254 | — |
| Research Site | Louisville | Kentucky | 40213 | — |
| Research Site | Baltimore | Maryland | 21229 | — |
| Research Site | Potomac | Maryland | 20854 | — |
| Research Site | Ypsilanti | Michigan | 48197 | — |
| Research Site | Kansas City | Missouri | 64114 | — |
| Research Site | Albany | New York | 12205 | — |
| Research Site | Laurelton | New York | 11413 | — |
| Research Site | Greensboro | North Carolina | 27408 | — |
| Research Site | Raleigh | North Carolina | 27609 | — |
| Research Site | Rocky Mount | North Carolina | 27804 | — |
| Research Site | Statesville | North Carolina | 28625 | — |
| Research Site | Dayton | Ohio | 45424 | — |
| Research Site | Tulsa | Oklahoma | 74133 | — |
| Research Site | DuBois | Pennsylvania | 15801 | — |
| Research Site | Newport | Pennsylvania | 17074 | — |
| Research Site | Gaffney | South Carolina | 29340 | — |
| Research Site | Franklin | Tennessee | 37067 | — |
| Research Site | Knoxville | Tennessee | 37912 | — |
| Research Site | Dallas | Texas | 75254 | — |
| Research Site | Morgantown | West Virginia | 26501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07667803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07667803 live on ClinicalTrials.gov.